Clearmind Medicine submits PCT patent applications for MDMA, Ibogaine, and Ketamine compounds with Palmitoylethanolamide.

Clearmind Medicine, a psychedelic-focused biotech firm, has submitted three new international patent applications under the Patent Cooperation Treaty (PCT) for MDMA, Ibogaine, and Ketamine compounds. The patent applications involve novel proprietary compositions with Palmitoylethanolamide (PEA), an active ingredient in SciSparc's proprietary CannAmide. This collaboration enhances Clearmind's intellectual property protection and expands its leadership in the psychedelic space.

February 27, 2024
7 Articles